Home › Macular Degeneration › NCT06489873
Lutein, Zeaxathin, and Fish Oil Supplementation
The Role of Lutein, Zeaxanthin, and Fish Oil on Cognitive Function and Bone Health in Healthy Adults
Who can join
Ages 18 to 45 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * \<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire. Exclusion Criteria: * allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.
About the study
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults.
The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months?
Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation.
Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density.
Participants will be asked to take either a LZF supplement or placebo daily for 6 months.
What is being tested
- Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF) (dietary supplement)
- Placebo Comparator (dietary supplement)
Sponsor: Texas A&M University · Participants: 80 · Started: Feb 7, 2024
Contact the study team
- Karen M Beathard, PhD · Phone: 979-220-2281
- Steven E Riechman, PhD · Phone: 979-862-3213
Official record on ClinicalTrials.gov — NCT06489873
Locations in the U.S.
| Texas | Gilchrist Building, College Station |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.